RNS Number : 2415X
N4 Pharma PLC
26 August 2020

26 August 2020

**N4 Pharma plc**

**("N4 Pharma" or the "Company")**

**Exercise of Warrants and Issue of Equity**

N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, announces that it has received notification to exercise warrants representing 2,424,062 ordinary shares of 0.4 pence each ("Ordinary Shares") in the Company for total consideration of £96,962.48. Following this exercise, there are no further warrants outstanding with an exercise price of 4p pursuant to the Company's announcement of 18 June 2020.

Application has been made for the 2,424,062 new Ordinary Shares to be admitted to trading on AIM ("Admission"), which is expected to occur at 8.00 a.m. on or around 2 September 2020. The new Ordinary Shares will rank pari passu with the existing Ordinary Shares. The Company does not hold any Ordinary Shares in treasury.

Following Admission and for the purposes of the Disclosure Guidance and Transparency Rules, the Company's total issued share capital will consist of 154,730,349 Ordinary Shares. Shareholders may use this figure as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the issued share capital of the Company.

**Enquiries:**

**N4 Pharma plc**
Nigel Theobald, CEO
Luke Cairns, Executive Director
Via IFC Advisory

**SP Angel Corporate Finance LLP**
Tel: +44(0)20 3470 0470

*Nominated Adviser and Joint Broker*
Matthew Johnson/Caroline Rowe (Corporate Finance)
Vadim Alexandre/Abigail Wayne/Rob Rees (Corporate Broking)

| | |
|---|---|
| **Turner Pope Investments (TPI) Limited**<br>*Joint Broker*<br>Andy Thacker | Tel: +44(0)20 3657 0050 |
| **IFC Advisory Ltd**<br>*Financial PR*<br>Graham Herring<br>Zach Cohen | Tel: +44(0)20 3934 6630 |

**About N4 Pharma**

N4 Pharma is a specialist pharmaceutical company developing a novel delivery system for cancer and vaccine treatments using its unique silica nanoparticle delivery system called Nuvec®.

N4 Pharma's business model is to partner with companies developing novel antigens for cancer and vaccine treatments to use Nuvec® as the delivery vehicle to get their antigen into cells to express the protein needed for the required immunity. As these products progress through pre clinical and clinical programs, N4 Pharma will seek to receive up front payments, milestone payments and ultimately royalty payments once products reach the market.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

IOESEMFLMESSELA